David A. Eagle, MD, New York Cancer & Blood Specialists, discusses the present state of treatment for cancer, which often sees patient financial concerns outweighed by the cost of treatment.
David A. Eagle, MD, chair of legislative affairs and patient advocacy at New York Cancer & Blood Specialists, discusses the present state of treatment for cancer, which often sees patient financial concerns outweighed by the cost of treatment. In this interview from our recent Institute for Value-Based Medicine® meeting in New York City on February 8, he addresses potential legislative focus areas to make inroads in this conflict.
Transcript
Can you discuss some of the top legislative priorities that aim to avoid patient financial toxicity but that still consider payer needs and priorities?
I think that’s the heart of the question in modern oncology. We’re in the middle of this tension. We have just enormous advancing scientific progress, but that’s creating enormous financial pressures on the systems. Cancer patients want the best treatment that they can get, and they deserve that. We have an insurance system, unfortunately, that is built around a permanent care model of cost sharing, which just doesn’t work that well with modern oncology. There really aren’t a lot of substitute products, sometimes, for patients.
I think the other important question moving forward, in addition to the finances, is: Who makes the clinical decisions for the patients? I think, as the oncologists, we want to make those decisions for the patients. We know the patients, we kind of know their personal situation, but more and more I think it’s getting harder and harder for us to make sure we have all the clinical authority over what happens to the patients as well.
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More